Tetanus primer significantly improves survival after immunotherapy for glioblastoma
the ONA take:
A study led by Duke Cancer Institute researchers demonstrated that an innovative pretreatment can enhance the effectiveness of immunotherapy for glioblastoma, dramatically improving patient survival.
Earlier research findings showed that glioblastoma tumors harbor a strain of cytomegalovirus (CMV) not present in the brain tissue around the tumor. This provides a natural target for immunotherapy.
Using dendritic cells, the researchers created a vaccine for the tumor. Patients with glioblastoma typically survive for little more than 1 year after diagnosis; however, after receiving the immunotherapy, half lived nearly 5 years or longer from their diagnosis.
Looking to expand on the effectiveness of the treatment, the researchers chose to use a shot of tetanus/diphtheria toxoid to incite the patient’s immune system.
In a blinded trial involving 12 patients with brain tumor, half were randomly selected to receive the tetanus shot; the other half received a placebo injection. The patients who received the tetanus shot had significantly longer survival than those who received the dendritic cell therapy alone (51-101 months vs 11.6 months).
One patient in the tetanus group continues to show no tumor growth and is still alive 8 years after the treatment.
An innovative pretreatment can enhance the effectiveness of immunotherapy for glioblastoma, dramatically improving patient survival.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|